Can gliotoxin and mycophenolic acid alter immune processes without proving neural autoimmunity?

Gliotoxin and mycophenolic acid (MPA) each have well-established biologic activities capable of altering immune processes, but these mechanisms do not make a urinary detection result proof of a neurologic autoimmune cause.

Mechanistic and immune effects

• Gliotoxin has a reducible disulfide that undergoes intracellular redox cycling, generating reactive oxygen species and forming mixed disulfides with protein thiols. This can disrupt thiol-dependent redox regulation and contribute to mitochondrial signaling, cytochrome-c release, caspase activation, and apoptosis.
• Functional immune suppression is demonstrated in several human immune-cell systems. In primary macrophages, gliotoxin reduced Fcγ-receptor-mediated phagocytosis across 62.5–1,000 ng/mL; at 50 nM during 18–48 hours, reported as non-cytotoxic, it reduced leukotriene B4 synthesis and phagocytosis. Neutrophil phagocytosis/ROS production and T-cell NF-κB signaling (reported at 306 nM) are also impaired.

MPA mechanism and clinical relevance

• MPA selectively and reversibly inhibits IMPDH, particularly type II, reducing de novo GMP and intracellular GTP/dGTP. Cellular IMPDH inhibition exceeded 70% at peak concentrations in the underlying evidence.
• Activated human lymphocyte proliferation was inhibited from about 0.1 μM, with near-maximal inhibition around 10 μM. 1 μM MPA caused T-cell G1 arrest; guanosine reversed both proliferation and cell-cycle effects, strongly supporting guanine-nucleotide depletion rather than nonspecific toxicity. This immunosuppression can increase infection susceptibility, particularly with higher exposure or concurrent immunosuppressants.

Biomarker interpretation

• Urinary gliotoxin or MPA establishes only that an analyte was measured. It does not determine source, route, absorbed dose, clinically harmful exposure, or causation. No validated urinary threshold predicts neural autoimmunity, and MPA results require exclusion of medication-related exposure.

Bottom line

• Both compounds have credible redox and immunosuppressive mechanisms, but exposure biomarkers alone cannot establish that either caused neural autoimmunity; causal attribution requires phenotype-driven neurologic evaluation and validated corroborative testing.